Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | ECE1 | P42892 | 1/20 | 0.49 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.47 |
| ▸ | GHSR | Q92847 | 2/20 | 0.47 |
| ▸ | RUVBL1 | Q9Y265 | 4/20 | 0.46 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.44 |
| ▸ | NPY1R | P25929 | 1/20 | 0.44 |
| ▸ | NPY2R | P49146 | 1/20 | 0.44 |
| ▸ | NPY4R | P50391 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4888158 | 0.84 | BDKRB2 (0.51) | UTS2RGHSRRUVBL1BDKRB2 | |
| SCHEMBL4888144 | 0.83 | UTS2R (0.47) | UTS2RGHSRRUVBL1BDKRB2 | |
| Hydrochloric Acid SCHEMBL6290405 | 0.82 | RUVBL1 (0.54) | UTS2RGHSRRUVBL1 | |
| Hydrochloric Acid SCHEMBL6287792 | 0.82 | RUVBL1 (0.54) | UTS2RGHSRRUVBL1 | |
| SCHEMBL14111057 | 0.79 | GHSR (0.46) | GHSR | |
| SCHEMBL4885605 | 0.79 | KDM1A (0.47) | NPY1R | |
| SCHEMBL4886967 | 0.78 | CHRNB2 (0.47) | BDKRB2 | |
| SCHEMBL4887077 | 0.78 | PLG (0.45) | — | |
| SCHEMBL4884651 | 0.78 | NTMT1 (0.46) | — | |
| SCHEMBL29603261 | 0.77 | KDM4E (0.59) | ACEUTS2RGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | MME 484/4885ACE 282/4885ECE1 1442/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | MME 1824/4885ACE 891/4885ECE1 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.